The Pan American Health Organization (PAHO) will present international locations all through the Americas, together with the Caribbean, with reasonably priced entry to the vaccine in opposition to respiratory syncytial virus (RSV) beginning within the first quarter of 2025.
RSV is a number one reason for pediatric hospitalization and loss of life from respiratory infections throughout the first six months of life.
PAHO introduced that roughly 13 million youngsters born within the area annually may gain advantage from this vaccination program when administered to pregnant girls.
Following suggestions from PAHO’s Advisory Committee on Immunization (ACIP) in November 2023, the vaccine needs to be administered to pregnant girls between 32 and 36 weeks of gestation. This timing is essential, as maternal antibodies present safety in opposition to RSV for roughly six months after beginning – the interval when infants face the very best threat of extreme illness.
“This technique ensures efficient safety for the new child and reduces the danger of preterm beginning,” PAHO officers acknowledged.
– Commercial –
At present, the World Well being Group (WHO) has authorized just one vaccine for stopping RSV-related illnesses in infants. Nations within the area can entry this vaccine by way of PAHO starting in 2025.
The initiative will likely be applied by way of PAHO’s Regional Revolving Fund, a cooperative mechanism with over 40 years of expertise. The Fund offers technical assist and facilitates bulk buying of greater than 60 high quality organic merchandise at reasonably priced costs for taking part nations.
